AI/ML Driving Clinical Outcomes
Harshit Jain, MD, Founder and Global CEO, Doceree
Artificial intelligence (AI) and machine learning (ML) are revolutionising pharma marketing by driving personalized engagement, predictive analytics, and improved clinical outcomes. These technologies enable targeted patient outreach, optimise drug promotion strategies, and enhance decision-making with real-time data insights. By leveraging AI-driven models, pharma companies can improve treatment adherence, patient outcomes, and overall healthcare efficiency.
1. How do you see the convergence of AI/ML and pharma marketing evolving to directly influence clinical outcomes rather than just brand visibility?
I think the convergence of AI and machine learning with pharma marketing is going well beyond building brands; it's beginning to significantly influence clinical decision-making. With the capacity to process large amounts of real-world data, these technologies are assisting in determining the optimal times to provide clinically relevant messaging to healthcare professionals.
To illustrate, programmatic platforms today can present therapeutic insights from context, e.g., patient histories or prescribing patterns, at the point of care. This opens up possibilities for reinforcing guideline-driven treatment decisions and ensuring evidence-based practice. Looking ahead, I envision AI/ML playing a key role in medical communication at scale to be personalised, i.e., not only timely but also relevant to clinical need. That, to my mind, is how pharma marketing can be a real lever for improved patient outcomes.
2. Can you elaborate on the role of real-time data processing in AI-driven platforms in bridging the gap between drug promotion and patient adherence?
Real-time data processing is one of the strongest enablers of successful engagement in healthcare today. I've witnessed how AI-powered platforms, powered by real-time data, can identify changes in behavior or drop-off points along a patient care pathway and send timely, context-specific messages to healthcare practitioners. These are moments, usually just prior to a prescription being written or a therapy selection being made, key to reinforcing adherence messaging. Instead of static campaigns, real-time capability enables pharmaceutical brands to reinforce clinical conversation dynamically, bridging the gap between promotion and long-term patient outcomes. Not about influencing prescription but about remaining relevant along the treatment pathway, where adherence is gained or lost.
3. In what ways have AI-powered predictive analytics redefined how pharma companies approach treatment pathways and patient segmentation?
To me, predictive analytics has changed the mindset from reactive to proactive in healthcare marketing. Rather than just finding the patient after a diagnosis, AI is now assisting in finding patients most likely to be at risk so that we can facilitate interventions sooner in the care continuum.
Patient segmentation has moved from broad demographics to micro-segments based on behavior patterns, clinical history, and even prescribing behavior. Such depth enables pharma companies to create more relevant, more personal engagement strategies, ones that acknowledge where a patient or health professional is in the treatment process. Lastly, AI not only informs better segmentation but also makes possible a more compassionate and accurate way of directing treatment paths, and therefore makes each message more timely, relevant, and clinically focused.
4. How is AI/ML being leveraged to transform point-of-care communication and drive measurable changes in prescribing behavior?
One of the most exciting trends, I think, is how AI and machine learning are enabling point-of-care communication to become more responsive and intelligent. Now we can deliver highly contextualised messages to clinicians, not at any time, but precisely when they're making those most important clinical decisions—i.e., when they are tending to the patients.
5. What are the most significant barriers you've observed in integrating AI into clinical decision support systems, and how can the industry overcome them?
One of the persistent issues that has stuck with me is trust, both in the technology itself and in the delivery of insights. Clinicians are understandably wary of incorporating AI recommendations into their workflow, particularly when the logic behind such suggestions is not made explicit. If an algorithm can't explain why it's recommending a given course of action, it quickly loses credibility with the very professionals it's intended to help.
Another significant stumbling block is interoperability. Clinical decision support systems tend to have to operate within a convoluted web of EHR platforms and hospital IT environments that weren't designed with AI in mind. Integrating sophisticated tools into these systems without disrupting current workflows is in no way easy.
To overcome these hurdles, I think the industry must emphasise three principles: transparency, relevance, and integration. AI systems must be transparent, not simply accurate. They must give insight that is clinically useful, not merely statistically fascinating. And lastly, they must integrate into current clinical workflows seamlessly, not require providers to toggle between isolated systems.
We’re making progress, but success will require continued collaboration between technologists, healthcare providers, and regulatory bodies to build solutions that are as practical as they are innovative.
6. With the growing emphasis on data privacy and compliance, how do AI algorithms balance personalisation in pharma marketing without compromising patient confidentiality?
AI-driven pharma marketing increasingly depends on privacy-first tech such as anonymised data sets, federated learning, and contextual targeting. These techniques enable us to send relevant messages without reviewing any discernible patient data. The aim is to recognise patterns in behavior, not identities, prioritising compliance while facilitating meaningful engagement.
That’s why I always encourage pharma marketers to carefully review how compliant partners actually are. In the modern regulatory environment, compliance can’t be an afterthought; it must be embedded in every level of your strategy. The appropriate partner will not only ensure that you stay on the correct side of regulations, but will also safeguard brand reputation, minimise risk, and ensure that your personalisation efforts are ethical and sustainable. It is not about who can get the job done; it is about who can do it responsibly.
7. Could you discuss the impact of AI/ML in shaping omnichannel engagement strategies for physicians and how that correlates with improved clinical outcomes?
AI and ML have enabled omnichannel strategies to be much smarter and more responsive. Rather than mass messaging, we can now customise based on a physician's specialty, behavior, and preferred channels, whether email, EHRs, medical sites, or point-of-care platforms.
By linking involvement with clinical settings and timing, these approaches yield improved recall of information and impact prescribing behavior more significantly. When doctors are given the proper message at the appropriate time, it logically leads to improved treatment choices and eventually, improved patient outcomes.
8. How can AI help mitigate disparities in healthcare delivery by identifying underrepresented or misdiagnosed patient populations?
I've witnessed firsthand the ability of AI to shed light on disparities that are often invisible in conventional healthcare systems. A particularly dramatic example was the way machine learning detected a persistent underdiagnosis pattern among a particular ethnic group across several regions, something clinicians weren't necessarily seeking out. That finding wasn't just data; it was a wake-up call. By using AI to bring those blind spots into view, we can assist pharma marketers and health systems in aligning resources and education where they have the greatest need.
9. What advancements in natural language processing (NLP) have shown the most promise in extracting clinical intelligence from unstructured medical data?
What is thrilling for me today is the way in which NLP is not only being utilised to address challenging clinical issues, but to resolve pharma marketing’s very basics. New solutions are emerging that leverage NLP to decipher how HCPs search, communicate, and interact, and how they can be turned into strategic insights from unstructured interactions.
10. From a global perspective, how do AI-driven models need to adapt to address the diversity in clinical practice patterns and regulatory landscapes?
AI in healthcare must be context-aware in order to actually function worldwide. I've realised that for AI to function globally, it must be trained on diverse data reflecting local conditions, whether preferred European treatments or U.S. regulatory systems. Flexibility and sensitivity to culture aren't so much technical requirements; they're required so that useful, compliant results can be delivered in diverse healthcare systems.
11. How do you measure the ROI of AI-driven campaigns when the intended outcome is not just engagement but a shift in clinical behavior and patient outcomes?
To quantify ROI in AI-driven pharma campaigns, you have to look beyond the typical suspects like impressions or click-throughs. I'm interested in outcomes that directly map to clinical impact in the real world, e.g., more prescribing changes, more treatment initiation, or better long-term adherence. That requires triangulating across the data sources: HCP engagement metrics, EHR data, and patient-level outcomes (where available and compliant). It's also about identifying leading indicators, doctor behavior changes in how they engage with content or tools, that signal downstream treatment decisions. ROI here is actually a function of whether the AI intervention made better, earlier treatment decisions.
12. In what ways do AI and ML tools support closed-loop marketing ecosystems that extend into clinical efficacy and long-term patient outcomes?
AI and ML are leading the way in enabling closed-loop marketing ecosystems through the development of a continuous feedback cycle between HCP interaction, clinical decision-making, and patient outcomes. Value comes in how these technologies integrate data across touchpoints, where they monitor how an HCP is engaging with particular content, correlate that with prescribing behavior changes, and then correlate those changes with treatment adherence or clinical outcome, where applicable. This backchannel interaction not only informs marketing strategy but also optimises the strategy continuously in real time. AI models are then able to use that to guide future contact based upon what has been demonstrated to drive clinical effectiveness, eventually extending efforts to patient-centered, outcome-focused campaigns.
13. As pharma companies increasingly rely on AI for decision-making, what ethical considerations must be accounted for in ensuring unbiased, evidence-based interventions?
As AI continues to become more prominent at the pharmaceutical decision-making table, ethical consciousness is crucial. Algorithms need to be constructed using large, representative data sets to reduce bias, particularly where their outputs drive clinical behaviors.
14. What role do you envision for generative AI in enhancing provider-patient interactions, clinical documentation, and therapeutic guidance in the near future?
Generative AI has tremendous potential to improve a number of aspects in healthcare. I see its immediate impact to be in clinician documentation, automating note-taking, summarising patient history, and decreasing administrative loads so clinicians can devote more time to patient care. In interactions between providers and patients, generative AI can aid physicians with contextual real-time information presentation, allowing for more informed and compassionate conversations. In the realm of therapeutic advice, AI has the potential to combine vast clinical information in order to recommend optimised treatment outcomes based on specific cases. Naturally, this progress needs to be well-regulated and substantiated in accordance with clinical validation, but the trend is very promising.
Author Bio
Harshit Jain, MD, Founder and Global CEO of Doceree, the First Global Network of Physicianonly Platforms for Programmatic Marketing. With Doceree, he is aiming to address the acute problem of rising cost of healthcare by bringing in efficiency and effectiveness in marketing to Physicians by pharma brands on digital platforms with methodical use of data and creativity.
